Tris Pharma announced the acquisition of NextWave Pharmaceuticals, a wholly owned subsidiary of Pfizer, including two key Attention Deficit Hyperactivity Disorder (ADHD) treatments.    The acquisition further expands Tris’ portfolio of products for the treatment of patients with ADHD. The agreement includes the acquisition of Quillivant XR, the first and only marketed extended-release oral liquid methylphenidate, and QuilliChew ER, the first and only extended-release methylphenidat...